Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

Inclusion Criteria:

* Equal to or greater than 18 years of age
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
* Adequate organ function:

  * Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥60 mL/min.
  * Bilirubin ≤ the intuitional upper limits of normal
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to be within institutional normal range
  * Absolute neutrophil count (ANC) ≥1000mm³
  * Platelet count ≥100,000mm³
* Has the capability of understanding the informed consent document and has signed the informed consent document
* Sexually active participants (male and female) must use medically acceptable methods of contraception during the course of the study.
* Women of childbearing potential must have a negative pregnancy test at screening.
* Able to understand and comply with the requirements of the protocol

Exclusion Criteria:

* receiving investigational therapy (other than the investigational therapy under study)
* Have received investigational therapy within 30 days prior to first dose of study drug
* Patients who are unable to swallow capsules
* Patients with prior malignancies, other than squamous or basal cell carcinomas, unless disease free for ≥ 5 years
* Have had prior major surgery within 30 days prior to first dose of study drug
* The patient has active infection or fever \>38.5C within 3 days prior to first dose of study drug.
* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Unable or unwilling to stop taking vitamins, herbal remedies, or nonprescription medications
* Pregnant or breastfeeding
* Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee